Article Text

PDF
FRI0587 Different factors are related to recurrence of existing organ involvement and new development of organ involvement in igg4-related disease
  1. I Mizushima,
  2. S Tsuge,
  3. Y Fujisawa,
  4. S Hara,
  5. F Suzuki,
  6. K Ito,
  7. H Fujii,
  8. K Yamada,
  9. M Kawano
  1. Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Kanazawa, Japan

Abstract

Background IgG4-related disease (IgG4-RD) is a recently recognized systemic inflammatory disorder that can affect many organs [1]. In IgG4-RD, relapse including recurrence of existing organ involvement (REOI) and new development of organ involvement (NDOI) easily occurs during the clinical course, and its predictors have been suggested [2, 3]. However, differences between risk factors of REOI and those of NDOI have not been clarified.

Objectives This study aimed to clarify the respective risk factors of REOI and NDOI in IgG4-RD.

Methods We retrospectively investigated factors related to REOI and NDOI in 86 IgG4-RD patients whose follow-up period was more than 12 months. For assessment of factors related to REOI and NDOI, we performed uni- and multivariate Cox regression analysis. On stepwise multivariate analysis, we applied the variables with P<0.1 in univariate analysis and the predictors of relapse suggested in past reports (age, sex, serum IgG4, IgG, and IgE levels, eosinophil counts, and RF positivity) [2, 3], and used the forward selection method (including factors presenting with P<0.05).

Results The patients comprised 57 men and 29 women (mean age 65.9 years). Mean follow-up period was 63.1 months (range 14–150). At diagnosis, their mean serum IgG4 level was 718 mg/dL (range 10.7–3,610). Seventy-one patients were treated with glucocorticoid (GC). REOI was detected at 52.3 months (range 1.0–120) after the diagnosis in 20 patients, including 4 not receiving GC at that time. On the other hand, NDOI was detected at 37.6 months (range 5.0–120) after the diagnosis in 15 patients, including 8 not receiving GC then. In multivariate Cox regression analysis, blood eosinophil counts [per 100/μL, hazard ratio (HR) 1.072, 95% confidence interval (CI) 1.018–1.129, P=0.008] and continuation of GC (vs discontinuation or observation without GC, HR 0.245, 95% CI 0.076–0.793, P=0.019) had a significant impact on the time to NDOI, whereas age (per year, HR 0.942, 95% CI 0.899–0.986, P=0.011) and ANA positivity (vs negativity, HR 6.632, 95% CI 1.892–23.255, P=0.003) had a significant impact on the time to REOI.

Conclusions The present study suggests that the risk factors of REOI and NDOI in IgG4-RD are different.

References

  1. Stone JH et al. IgG4-related disease. N Engl J Med. 2012 Feb 9;366(6):539–51.

  2. Yamamoto M et al. Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatology (Oxford). 2015 Jan;54(1):45–9.

  3. Wallace ZS et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford). 2016 Jun;55(6):1000–8.

References

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.